Identification and characterization of in vitro, in vivo, and reactive metabolites of tandutinib using liquid chromatography ion trap mass spectrometry
- PMID: 33410830
- DOI: 10.1039/d0ay02106g
Identification and characterization of in vitro, in vivo, and reactive metabolites of tandutinib using liquid chromatography ion trap mass spectrometry
Abstract
Tandutinib (TND) is a novel, oral small molecule designed for treating acute myeloid leukemia (AML) by inhibiting type III receptor tyrosine kinases. This study reports the use of in silico, in vivo, and in vitro methods to investigate the metabolism and possible metabolic bioactivation of TND. First, in silico metabolism of TND was assessed using the WhichP450™ module of the StarDrop® software to determine labile sites of metabolism in the TND chemical structure. Second, the XenoSite reactivity model, a web-based metabolism prediction software, was used to determine probable bioactive centers. Based on the in silico outcomes, a list of predicted metabolites and reactive intermediates were prepared. Third, in vitro and in vivo experiments were performed. In vitro TND metabolites were generated through incubation of TND with rat liver microsomes (RLMs). Another incubation of TND with RLMs was separately performed in the presence of GSH and KCN to check for the generation of reactive intermediates (soft and hard electrophiles). In vitro phase II metabolism was assessed by incubation of TND with isolated perfused rat hepatocytes. In vivo metabolism was investigated by oral gavage of TND (37 mg kg-1) in Sprague Dawley rats. Five in vitro phase I metabolites, one in vitro phase II and five reactive iminium intermediates (cyano adducts), six in vivo phase I, and one in vivo phase II metabolites of TND were characterized. The in vitro and in vivo metabolic pathways involved were O-dealkylation, α-hydroxylation, α-carbonyl formation, reduction, glucuronide, and sulfate conjugation. No GSH conjugate or its catabolic products were detected either in vitro or in vivo. Two cyclic tertiary rings of TND (piperazine and piperidine) were metabolically bioactivated to generate reactive iminium intermediates forming cyano adducts with KCN. The formed reactive intermediates may be the reason behind TND toxicity. In silico toxicological studies were performed for TND and its related (in vitro and in vivo) metabolites were evaluated using the DEREK software tool.
Similar articles
-
Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites.RSC Adv. 2020 Apr 23;10(28):16231-16244. doi: 10.1039/c9ra10871h. eCollection 2020 Apr 23. RSC Adv. 2020. PMID: 35498820 Free PMC article.
-
Profiling of in vivo, in vitro and reactive zorifertinib metabolites using liquid chromatography ion trap mass spectrometry.RSC Adv. 2022 Jul 21;12(32):20991-21003. doi: 10.1039/d2ra02848d. eCollection 2022 Jul 14. RSC Adv. 2022. PMID: 35919181 Free PMC article.
-
Investigation of Fenebrutinib Metabolism and Bioactivation Using MS3 Methodology in Ion Trap LC/MS.Molecules. 2023 May 22;28(10):4225. doi: 10.3390/molecules28104225. Molecules. 2023. PMID: 37241965 Free PMC article.
-
Piperazine ring toxicity in three novel anti-breast cancer drugs: an in silico and in vitro metabolic bioactivation approach using olaparib as a case study.Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396(7):1435-1450. doi: 10.1007/s00210-023-02413-9. Epub 2023 Feb 4. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36738368
-
Role of cyclic tertiary amine bioactivation to reactive iminium species: structure toxicity relationship.Curr Drug Metab. 2011 Jan;12(1):35-50. doi: 10.2174/138920011794520044. Curr Drug Metab. 2011. PMID: 21222587 Review.
Cited by
-
Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform.Front Pharmacol. 2022 Jul 1;13:899536. doi: 10.3389/fphar.2022.899536. eCollection 2022. Front Pharmacol. 2022. PMID: 35847040 Free PMC article.
-
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment.Curr Med Chem. 2024;31(29):4657-4686. doi: 10.2174/0109298673277543231205072556. Curr Med Chem. 2024. PMID: 38204232 Review.
-
Bioactivation and reactivity research advances - 2021 year in review.Drug Metab Rev. 2022 Aug;54(3):246-281. doi: 10.1080/03602532.2022.2097254. Epub 2022 Aug 5. Drug Metab Rev. 2022. PMID: 35876116 Free PMC article. Review.
-
Antiviral activity of some benzo[g]quinazolines against coxsackievirus B4: biological screening and docking study.Pharmacol Rep. 2023 Aug;75(4):962-978. doi: 10.1007/s43440-023-00495-z. Epub 2023 May 21. Pharmacol Rep. 2023. PMID: 37210695 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources